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Abstract 
The epilepsies are commonly accompanied by widespread abnormalities in cerebral white 
matter. ENIGMA-Epilepsy is a large quantitative brain imaging consortium, aggregating data 
to investigate patterns of neuroimaging abnormalities in common epilepsy syndromes, 
including temporal lobe epilepsy, extratemporal epilepsy, and genetic generalized epilepsy. 
Our goal was to rank the most robust white matter microstructural differences across and within 
syndromes in a multicentre sample of adult epilepsy patients. Diffusion-weighted MRI data 
were analyzed from 1,069 non-epileptic controls and 1,249 patients: temporal lobe epilepsy 
with hippocampal sclerosis (N=599), temporal lobe epilepsy with normal MRI (N=275), 
genetic generalized epilepsy (N=182) and nonlesional extratemporal epilepsy (N=193). A 
harmonized protocol using tract-based spatial statistics was used to derive skeletonized maps 
of fractional anisotropy and mean diffusivity for each participant, and fiber tracts were 
segmented using a diffusion MRI atlas. Data were harmonized to correct for scanner-specific 
variations in diffusion measures using a batch-effect correction tool (ComBat). Analyses of 
covariance, adjusting for age and sex, examined differences between each epilepsy syndrome 
and controls for each white matter tract (Bonferroni corrected at p<0.001). Across “all 
epilepsies” lower fractional anisotropy was observed in most fiber tracts with small to medium 
effect sizes, especially in the corpus callosum, cingulum and external capsule. Less robust 
effects were seen with mean diffusivity. Syndrome-specific fractional anisotropy and mean 
diffusivity differences were most pronounced in patients with hippocampal sclerosis in the 
ipsilateral parahippocampal cingulum and external capsule, with smaller effects across most 
other tracts. Those with temporal lobe epilepsy and normal MRI showed a similar pattern of 
greater ipsilateral than contralateral abnormalities, but less marked than those in patients with 
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hippocampal sclerosis. Patients with generalized and extratemporal epilepsies had pronounced 
differences in fractional anisotropy in the corpus callosum, corona radiata and external 
capsule, and in mean diffusivity of the anterior corona radiata. Earlier age of seizure onset and 
longer disease duration were associated with a greater extent of microstructural  abnormalities 
in patients with hippocampal sclerosis. We demonstrate microstructural abnormalities across 
major association, commissural, and projection fibers in a large multicentre study of epilepsy. 
Overall, epilepsy patients showed white matter abnormalities in the corpus callosum, cingulum 
and external capsule, with differing severity across epilepsy syndromes. These data further 
define the spectrum of white matter abnormalities in common epilepsy syndromes, yielding 
new insights into pathological substrates that may be used to guide future therapeutic and 
genetic studies. 
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Introduction 
 
Epilepsy affects over 50 million people worldwide (Bell et al., 2014).  Focal 
epilepsies account for around 60% of all adult epilepsy cases, and temporal lobe epilepsy 
(TLE) is the most common (Téllez-Zenteno and Hernández-Ronquillo, 2012).  TLE is 
associated with hippocampal sclerosis (HS) in 60-70% of cases (Coan and Cendes, 2013).  
Among adult epilepsy patients, up to 20% have genetic generalized epilepsy (GGE), with 
bilateral synchronous seizure onset and a presumed genetic background (Scheffer et al., 
2017). These epilepsy syndromes are frequently studied in isolation and may have distinct 
pathophysiological substrates and mechanisms. Their unique and shared biological pathways 
are beginning to be unraveled using population genetics (International League Against 
Epilepsy Consortium on Complex Epilepsies, 2018) and transcriptomics (Altmann et al., 
2017), paving the pathway for potential novel treatments.  
Once considered primarily “gray matter” diseases, brain imaging studies with 
diffusion magnetic resonance imaging (dMRI) has helped reveal that both focal and 
generalized epilepsies represent network disorders with widespread white matter alterations 
even in the absence of visible MRI lesions (Engel et al., 2013).  Patients with TLE, 
particularly those with HS, may exhibit white matter abnormalities both proximal to and 
distant from the seizure focus, often most pronounced in the ipsilateral hemisphere (Focke et 
al., 2008; Ahmadi et al., 2009; Labate et al., 2015; Caligiuri et al., 2016).  Studies in patients 
with GGE have demonstrated microstructural compromises in frontal and parietal regions 
bilaterally, and in thalamocortical pathways (Keller et al., 2011; Lee et al., 2014; Szaflarski 
et al., 2016). White matter disruption in epilepsy is also linked to cognitive (McDonald et al., 
2008; Yogarajah et al., 2008, 2010) and postsurgical seizure (Bonilha et al., 2015; Keller et 
al., 2015, 2017; Gleichgerrcht et al., 2018) outcomes, indicating the importance of white 
matter networks in the pathophysiology and co-morbidities of epilepsy.   
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Meta-analyses and single-site studies of dMRI suggest widespread microstructural 
abnormalities in patients with focal epilepsy affecting association, commissural, and 
projection fibers, whereas microstructural differences in GGE are reportedly less pronounced 
(Otte et al., 2012; Slinger et al., 2016). Unfortunately, the exact tracts, spatial pattern, and 
extent of damage reported varies across studies, making it hard to draw conclusions about 
syndrome-specific and generalized white matter pathology in epilepsy.  Inconsistencies may 
be due, in part, to small sample sizes at individual centers, which may lack power to detect 
reliable differences across a large number of white matter tracts and multiple diffusion 
measures.  Methods for image acquisition, processing, and tract selection also differ greatly 
across studies, adding other sources of variability. Few studies consider white matter 
abnormalities as a function of sex, age, and key clinical characteristics leading to multiple 
uncertainties in the findings.  Although meta-analyses reduce some of these limitations, 
harmonizing the image processing and data analysis in a consortia effort, alleviates some of 
the known sources of variation and allows for the statistical modeling of other population 
differences. Furthermore, pooling raw data across a large number of centers in a mega-
analysis1 may offer greater power to detect group effects and enable cross-syndrome 
comparisons that have not previously been possible.  Further, due to the collation of world-
wide harmonized image analysis protocols, analysis, and reporting of results, white matter 
differences in epilepsy can now be directly compared to those of other neurological and 
psychiatric disorders, highlighting pathology that may be unique to epilepsy and/or its 
treatments. 
Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) is a global 
initiative, combining individually collected samples from studies around the world into a 
 
1 A meta-analysis aggregate of summary results (e.g. effect size estimates, standard errors, and confidence 
intervals) across studies, but a mega-analysis aggregates individual participant data across studies, and may 
allow additional data harmonization. For an empirical comparison between the two techniques using structural 
MRI data, please refer to (Boedhoe et al., 2018). 
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single large-scale study, with coordinated image processing, and integrating imaging, 
phenotypic, and genomic data from hundreds of research centers worldwide (Thompson et 
al., n.d.). Standardized protocols for image processing, quality assurance, and statistical 
analyses were applied using the validated ENIGMA-dMRI protocols for multi-site diffusion 
tensor imaging (DTI) harmonization, http://enigma.usc.edu/ongoing/dti-working-group/ 
(Jahanshad et al., 2013; Kochunov et al., 2014, 2015) 
Our primary goal was to identify and rank the most robust white matter 
microstructural alterations across and within common epilepsy syndromes in a sample of 
1,249 adult epilepsy patients and 1,069 healthy controls across nine countries from North and 
South America, Europe and Australia. First, we studied all patients in aggregate (“all 
epilepsies”) compared to age and sex matched controls, followed by targeted analyses 
focusing on patients with right and left TLE-HS, right and left non-lesional TLE (TLE-NL), 
nonlesional extratemporal epilepsy (ExE), and GGE. We characterize effect size (ES) 
differences across and within these epilepsy syndromes in fractional anisotropy (FA) and 
mean diffusivity (MD), as well as axial (AD) and radial (RD) diffusivity.  We also examine 
regional white matter associations with age of seizure onset and disease duration.   
We hypothesized that, compared to controls, each patient group would show white 
matter alterations beyond the suspected epileptogenic region, with unique patterns in each 
group.  Specifically, we hypothesized that patients with TLE would show the most 
pronounced alterations in ipsilateral temporo-limbic regions, most notably in TLE-HS.  We 
hypothesized that patients with GGE would show bilateral fronto-thalamocortical alterations. 
We also hypothesized that common white matter alterations would emerge across the patient 
groups and that many of these regional alterations would correlate with disease duration and 
be similar to those seen in other brain disorders.   
.CC-BY-ND 4.0 International licensepreprint (which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for thisthis version posted December 20, 2019. . https://doi.org/10.1101/2019.12.19.883405doi: bioRxiv preprint 
  
Materials and methods 
All study participants provided written informed consent for the local study, and the 
local institutional review boards and ethics committees approved each included cohort study. 
Study sample 
This study from the ENIGMA-Epilepsy working group consists of 21 cohorts from 
nine different countries and includes dMRI scans from 1,069 healthy controls and 1,249 adult 
epilepsy patients. Demographic and clinical characteristics of the samples are presented in 
Table 1 (by site) and Table 2 (across site). An epilepsy specialist assessed seizure and 
syndrome classifications at each center, using the International League Against Epilepsy 
(ILAE) criteria. For the TLE subgroups, we included anyone with the typical electroclinical 
constellation of this syndrome (Berg et al., 2010).  All TLE-HS patients had a 
neuroradiologically-confirmed diagnosis of unilateral atrophy and increased T2 signal on 
clinical MRI, whereas all of the TLE-NL patients had a normal MRI undertaken at the same 
time as the analyzed dMRI scan.  Participants with a normal MRI and frontal, occipital, or 
parietal epilepsy were labelled as ExE. Participants with tonic-clonic, absence or myoclonic 
seizures with generalized spike-wave discharges on EEG were included in the GGE group. 
We excluded participants with a progressive disease (e.g., Rasmussen’s encephalitis), 
malformations of cortical development, tumors or prior neurosurgery.  Participants were 
between 18 and 70 years of age. 
  
Image processing and analysis 
Scanner descriptions and acquisition protocols for all sites are provided in 
Supplementary Table 1. Individual scanners that used different acquisition protocols are 
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listed as separate scanner instances. Each site conducted the preprocessing of diffusion-
weighted images, including eddy current correction, echo-planar imaging (EPI)-induced 
distortion correction, and tensor estimation. Next, diffusion-tensor imaging (DTI) images 
were processed using the ENIGMA-DTI protocols. These image processing and quality 
control protocols are freely available at the ENIGMA-DTI  
(http://enigma.ini.usc.edu/ongoing/dti-working-group/) and NITRC 
(https://www.nitrc.org/projects/enigma_dti/) webpages. Measures of FA, MD, AD and RD 
were obtained for 38 regions of interest using the Johns Hopkins University (JHU) atlas 
(Figure 1).  
For analyses of all patients and for each syndrome, we used the left and right tracts, 
the midline structures of the body (BCC), genu (GCC), and splenium (SCC) of the corpus 
callosum and the average diffusion metric (FA/MD/AD/RD) across the whole brain (38 
ROIs). Corrections for multiple comparisons were carried out for each epilepsy syndrome, 
based on the number of ROIs: 34 bilateral white matter regions + BCC + GCC + SCC + 
Average FA=38 ROIs: Bonferroni-corrected threshold for significance p=0.05/38=0.001. 
Data harmonization 
The batch-effect correction tool, ComBat, was used to harmonize between-site and 
between-protocol variations in diffusion metrics as previously demonstrated (Fortin et al., 
2017). The method globally rescales the data (all ROIs for FA, MD, RD or AD separately) 
for each scanner instance using a z-score transformation map common to all features. 
ComBat uses an empirical Bayes framework (Johnson et al., 2007) to improve the variance of 
the parameter estimates, assuming that all ROIs share the same common distribution. Thus, 
all ROIs are used to inform the statistical properties of the scanner effects. We set each 
scanner instance as each individual scanner used in the collection of MR exams, and where 
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there were different scanning protocols used on the same scanner, each protocol was set as a 
different scanning instance. Scanner type was used as the batch effect and diagnosis (patients 
versus controls) and syndrome (GGE, TLE-HS, TLE-NL, and ExE) were used as the 
biological phenotypes of interest. This technique has been recently applied in other ENIGMA 
DTI investigations of brain disorders (Villalón-Reina et al., 2019; Zavaliangos-Petropulu et 
al., 2019).  
Statistical analysis 
Statistical analysis was performed in the Statistical Package for the Social Sciences 
(SPSS v26.0). Analysis of variance (ANOVA) was used to test for differences in 
demographic and clinical characteristics among the epilepsy syndromes.  To test for 
differences between syndromes and controls and to test for global effects of age at scan and 
sex on white matter, multivariate analysis of covariance (MANCOVA) was performed per 
diffusion metric, adjusting for age, age2 and sex.  Age2 was included in all analyses to model 
the non-linear effects of age on diffusivity measures (Lebel et al., 2012).  ANCOVAs were 
then performed of each patient syndrome compared to controls controlling for age, age2 and 
sex and Bonferroni corrected at p<0.001. Cohen’s d effect sizes (ES) were calculated for each 
right and left fiber tract between controls and each patient syndrome based on the estimated 
marginal means (adjusted for age, age2, and sex) and interpreted according to the following 
criteria:  small d=0.20-0.49 ; medium d=0.50-0.79; large d>=0.80 (Sawilowsky, 2009). 
Throughout the text and figures, positive ES values correspond to patients having higher 
values than controls, whereas negative ES values correspond to patients having lower values 
relative to controls. Partial correlations controlling for the same covariates were performed to 
evaluate the relationship between each fiber tract FA/MD and age of seizure onset and 
disease duration (corrected p<0.001). To demonstrate the most robust group differences, only 
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medium and large effects are discussed in the text (see Supplementary materials for all 
results: Tables 5-32 and Figures 5-6).     
 
   
.CC-BY-ND 4.0 International licensepreprint (which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for thisthis version posted December 20, 2019. . https://doi.org/10.1101/2019.12.19.883405doi: bioRxiv preprint 
  
 
Results 
Demographics 
Demographic and clinical characteristics of each sample are presented in Table 2.  
ANOVA revealed differences across the cohort in age [F(6, 2083) = 13.3, p<0.001)] and 
across the patient syndromes in age of seizure onset [F(5, 1095) = 6.3, p<0.001] and disease 
duration [F(5,1039) = 22.4, p<0.001].  Post-hoc comparisons revealed that controls were 
younger than both TLE-HS groups and older than patients with GGE and ExE (all p-
values<0.05).  Both TLE-HS groups and the left TLE-NL group were older than the GGE and 
ExE groups (p<0.05). The right TLE-HS group was older than both TLE-NL groups 
(p<0.05).   
The GGE and TLE-HS groups had an earlier age of seizure onset than the TLE-NL 
groups. Duration of illness in TLE-HS groups was longer than in all other groups. 
Data harmonization with ComBat 
Initial frequency plots revealed high variability in the distribution of diffusivity 
measures (e.g., mean FA, mean MD) among scanner instances (Fig. 2A). After batch 
correction with ComBat, the distributions were centered around a common mean (Fig. 2B), 
but maintained their expected association with age (Fig. 2C). Following this process, extreme 
ROI outliers beyond 3 SD were removed from the subsequent analysis (i.e., per ROI for a 
given subject, not per subject).  
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All epilepsies group  
Multivariate tests of within-subject effects 
Comparing the whole epilepsy group with healthy controls, significant differences 
were observed in FA (F(228,13452)=4.7, p<0.001, Pillai's Trace=0.44, partial η2=0.07), MD 
(F(228,11688)=2.8, p<0.001, Pillai's Trace=0.31, partial η2=0.05), RD (F(228,11790)=3.28, 
p<0.001, Pillai's Trace=0.36, partial η2=0.06), and AD (F(228,11946)=1.96, p<0.001, Pillai's 
Trace=0.22, partial η2=0.04). Sex, age, and age2 all significantly contributed to the model 
(see Supplementary Table 4).  Compared to females, males generally had higher FA, slightly 
higher RD and no difference in MD or AD.  
All epilepsies vs healthy controls 
The “all epilepsies” group showed lower FA than controls globally in 36 of 38 ROIs 
(p<0.001; Fig. 3, Supplementary Table 5), with medium ES observed for the average FA 
(d=-0.71), followed by external capsule (EC; left d=-0.64, right d=-0.63), body (d=-0.59) and 
genu (d=-0.59) of the corpus callosum (BCC and GCC), cingulate gyrus of the cingulum 
bundle (CGC, left d=-0.57, right d=-0.50), sagittal stratum (SS, left d=0.55, right d=0.52), 
anterior corona radiata (ACR, left d=-0.50, right d=-0.52), and left parahippocampal 
cingulum (CGH, d=-0.52).  
The “all epilepsies” group showed higher MD than the controls with small effect size 
in 27 ROIs (Fig. 4, Supplementary Table 12). Similar to the MD, patients showed higher RD 
with small effect size in 34 ROIs (Supplementary Fig. 1, Supplementary Table 19) with a 
medium-sized effect seen in the right EC (d=0.52). Small-sized effects were observed for AD 
in 8 ROIs (Supplementary Fig. 2, Supplementary Table 26).  
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Age of onset and disease duration 
Across all epilepsy patients, earlier age of onset was associated with lower FA across 
28 ROIs (r=0.1 to 0.3, p<0.001), higher MD in 16 ROIs, and higher RD in 28 ROIs 
(Supplementary Tables 33,35,37).  The most robust associations were observed between an 
earlier age of seizure onset and lower FA in the Average FA, GCC, and bilateral EC, and 
CGC (r’s between 0.16 and 0.19).  There were no significant relationships between age of 
onset and AD in the “all epilepsies” group (Supplementary Table 39).  
Across all epilepsy patients, disease duration showed significant but small effects on 
diffusivity measures (Supplementary Tables 34, 36, 38, 40). A longer disease duration was 
associated with lower FA in 14 ROIs, increased MD in 9 ROIs, and increased RD in 27 ROIs. 
Of note, longer disease duration was associated with lower FA in BCC, CGC, and EC, and 
with lower Average FA (r’s = -0.15 to -0.17). There were no significant relationships 
between disease duration and AD in all patients.  
TLE-HS group 
TLE-HS patients vs healthy controls 
Left TLE-HS patients (n=319) showed significantly lower FA than controls in 35 of 
38 ROIs (Fig. 3, Supplementary Table 6), with large ES differences in the left EC (d=-1.02), 
left CGH (d=-1.01), Average FA (d=-0.92), left CGC (d=-0.89), and left fornix/stria 
terminalis (FXST, d=-0.83). Medium-sized effects were observed in GCC (d=-0.79), left SS 
(d=-0.78), BCC (d=-0.75), right CGC (d=-0.68), right EC (d=-0.68), left superior longitudinal 
fasciculus (SLF, d=-0.67), left ACR (d=-0.66), left anterior limb of the internal capsule 
(ALIC, d=-0.61), left retrolenticular portion of the internal capsule (RLIC, d=-0.61), left 
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uncinate (UNC, d=-0.61), right SLF (d=-0.58), left PCR (d=-0.54), right ACR (d=-0.53), and 
right SS (d=-0.52).  
Significantly higher MD was observed in 28 ROIs (Fig. 4, Supplementary Table 13), 
with medium-sized effects in the left EC (d=0.69), left SS (d=0.66), and average MD 
(d=0.55). Left TLE-HS patients showed significantly higher RD in 33 of 38 ROIs 
(Supplementary Fig. 1, Supplementary Table 20). A large effect of higher RD was observed 
for the left EC (d=0.83), and medium-sized effects were seen for the left SS (d=0.79), left 
CGC (d=0.69), left CGH (d=0.67), average RD (d=0.66), right EC (d=0.61), left FXST 
(d=0.59), left ACR (d=0.57), SLF (left d=0.56, right d=0.53), right ACR (d=0.52), and left 
RLIC (d=0.51). Small-sized effects were observed for AD in 5 ROIs (Supplementary Figure 
2, Supplementary Table 27). 
Right TLE-HS patients (n=280) showed lower FA than controls in 26 of 38 ROIs 
(p<0.001; Fig. 3, Supplementary Table 7), with large effects observed for the average FA 
(d=-1.06), right CGH (d=-1.02), right EC (d=-0.99), right UNC (d=-0.90), BCC (d=-0.87), 
GCC (d=-0.85) and right SS (d=-0.83). Medium-sized effects were observed in the right ACR 
(d=-0.78), right CGC (d=-0.73), left EC (d=-0.68), left ACR (d=-0.68), left CGC (d=-0.68), 
left tapetum (TAP, d=-0.68), right PTR (d=-0.62), right FX/ST (d=-0.61), right SLF (d=-
0.59), right TAP (d=-0.59), right ALIC (d=-0.55), right PCR (d=-0.55), left SS (d=-0.55), and 
left SCR (d=-0.53).  
Higher MD in the patient group were observed in 23 ROIs (Fig. 4, Supplementary 
Table 14), with medium-sized effects shown in the right SS (d=0.67), right EC (d=0.62), right 
UNC (d=0.62), average MD (d=0.60) and right ACR (d=0.59). Significantly higher RD in the 
patient group were observed in 31 ROIs (Supplementary Figure 1, Supplementary Table 21), 
with a large effect observed for the right EC (d=0.84), and medium effects seen for the right 
SS (d=0.76), right UNC (d=0.72), average RD (d=0.70), right ACR (d=0.69), left EC 
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(d=0.63), right SLF (d=0.62), right CGH (d=0.61), right CGC (d=0.57), BCC (d=0.56), right 
FX/ST (d=0.52), and left ACR (d=0.51). Small effects were observed for AD in 6 ROIs 
(Supplementary Figure 2, Supplementary Table 28).  
Age of onset and disease duration 
For left TLE-HS, earlier age of onset was associated with lowerFA in 4 ROIs, 
including the Average FA, BCC, GCC, and left EC. Earlier age of seizure onset was 
associated with higher RD in 2 ROIs (Supplementary Tables 33,37).  There was no detected 
relationship between age of onset and either MD or AD in the left TLE-HS group 
(Supplementary Tables 35, 39).  
For right TLE-HS, earlier age of onset was related to lower FA across 9 ROIs, 
including the Average FA, BCC, SCC, right EC, left and right CGH, right PCR, and right 
SLF, increased MD in 7 ROIs, and increased RD in 7 ROIs (Supplementary Tables 33, 35, 
37). There was no detected relationship between age of onset and AD in the TLE-HS groups 
(Supplementary Table 39). 
For left TLE-HS patients, a longer disease duration was associated with lower FA in 4 
ROIs (BCC, bilateral CGC, and left EC) and higher RD in one ROI (left SS).  There were no 
significant relationships between disease duration and MD or AD (Supplementary Tables 34, 
36, 38, 40).  For right TLE-HS, disease duration showed significant small effects on 
diffusivity measures (Supplementary Tables 34, 36, 38, 40). A longer disease duration was 
associated with lower FA in 8 ROIs (Average FA and SCC, bilateral TAP, and right CGH, 
EC, PCR, and UNC), higher MD in 6 ROIs, and higher RD in 10 ROIs.  
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TLE-NL group 
TLE-NL vs healthy controls 
The left TLE-NL patients (n=162) showed significantly lower FA than controls in 20 
ROIs (p<0.001; Fig. 3, Supplementary Table 8) of small ES. MD was higher in one ROI, the 
right SLF (d=0.35, p<0.001, Fig. 4, Supplementary Table 15). Significantly higher  RD was 
observed in 6 ROIs (Supplementary Figure 1, Supplementary Table 22) of small ES. No 
significant effects of AD were detected (Supplementary Figure 2, Supplementary Table 29). 
Right TLE-NL patients (n = 113) showed significantly lower FA than controls in 19 
ROIs (p<0.001; Fig. 3, Supplementary Table 9), with medium-sized effects observed in the 
right EC (d=-0.64), right SS (d=-0.60), Average FA (d=-0.58), right CGH (d=-0.55), right 
CGC (d=-0.51) and right UNC (d=-0.50). MD was increased in three ROIs (p<0.001, Fig. 4, 
Supplementary Table 16), specifically the right EC (d=0.46), right UNC (d=0.42) and right 
SS (d=0.42). Significantly higher RD was observed in 4 ROIs (Supplementary Figure 1, 
Supplementary Table 23), with a medium-sized effect shown in the right EC (d=0.50). No 
significant effects of AD were detected (Supplementary Figure 2, Supplementary Table 30). 
Age of onset and disease of illness 
For left TLE-NL, no diffusivity measure was associated with earlier age of onset or 
duration of illness (Supplementary Tables 33-40).  
For right TLE-NL patients, younger age of onset and was related to lower FA in the 
right UNC (r=0.30, p<0.001), but not MD, AD, or RD (Supplementary Tables 33, 35, 37, 
39). Disease duration was also associated with decreased FA in the right UNC (r= =-0.37, 
p<0.001), but not MD, AD, or RD (Supplementary Tables 34, 36, 38, 40).  
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GGE group 
GGE patients vs healthy controls 
GGE patients (n=113) showed significantly lower FA than controls in 28 ROIs 
(p<0.001; Fig. 3, Supplementary Table 10), with medium-sized effects observed in the GCC 
(d=-0.57), left SLF (d=-0.57), left EC (d=-0.55), left RLIC (d=-0.51), right SLF (d=-0.51) 
and left PCR (d=-0.50). No significant effects were seen for MD or AD (Fig. 4, 
Supplementary Fig. 2, Supplementary Tables 17, 31), but small ESs were seen for RD (4 
ROIs, p<0.001, Supplementary Fig. 1, Supplementary Table 24). 
Age of onset and disease duration 
For GGE patients, there was no significant association between diffusivity measures 
and either age of onset of epilepsy, or its duration. 
 
ExE group 
ExE patients vs healthy controls 
ExE patients (n=193) showed significantly lower FA than controls in 33 ROIs 
(p<0.001; Fig. 1, Supplementary Table 11), with medium-sized effects observed for Average 
FA (d=-0.75), BCC (d=-0.65), GCC (d=-0.64), right ACR (d=-0.63), bilateral EC (left d=-
0.60, right d=-0.58), left ALIC (d=-0.57), left ACR (d=-0.55), and right SS (d=-0.51). Small-
sized effects were seen in MD (6 ROIs, p<0.001, Fig. 4, Supplementary Table 18) and RD 
(22 ROIs, p<0.001, Supplementary Figure 1, Supplementary Table 25). No significant effects 
were seen in AD (Supplementary Figure 2, Supplementary Table 32). 
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Age of onset and disease duration 
For ExE patients, there were no significant associations between diffusivity measures 
and either age of onset of epilepsy, or its duration. 
Cross-syndrome comparisons 
Post-hoc comparisons were conducted across the syndromes in the five ROIs that 
showed the largest ES in the “all epilepsies” analysis, namely Average FA/MD, ACR, BCC, 
CGC, and EC averaged across hemispheres (Figure 5). ANCOVAs, adjusting for age, age2, 
sex, age of seizure onset, and disease duration revealed significant group differences in 
Average FA [F (5, 874) = 3.8, p<0.05], as well as FA of the CGC [F(5, 874) = 5.0, p<0.05], 
and EC [F(5, 874) = 5.8, p<0.05].   
There were differences across syndromes or the Average MD [F(5, 874) = 5.3, 
p<.05], ACR [F(5, 874) = 3.8, p<0.05], BCC [F(5, 874) = 4.9, p<0.05], CGC [F(5, 874) = 
4.2, p<0.05], and the EC [F(5, 874) = 6.2, p<0.05]. Patients with left and right TLE-HS 
generally showed lower FA and higher MD than those with TLE and normal MRI, GGE in 
Average FA/MD, CGC, and the EC. The nonlesional groups (GGE, TLE-NL, and ExE) did 
not differ from one another.   
 
Comparisons with other disorders 
 Given the many common white matter FA differences observed across epilepsy 
syndromes, the question arises as to whether these effects are specific to epilepsy or also seen 
with other brain disorders.  Figure 6 displays ES differences observed in the “all epilepsies” 
group (n=1,249) relative to findings from four other ENIGMA working groups: 
schizophrenia (SCZ; n=1,984; mean age, 36.2; 67% men), 22q11 syndrome (n=334; mean 
age, 16.9; 54% men), bipolar disorder (BP; n=1,482; mean age, 39.6; 39.3% men), and major 
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depressive disorder (MDD; n=921; mean age, 40.7; 39% men).  The magnitude of the ESs 
were typically larger in epilepsy, compared to the other disorders for most white matter 
regions. Across the white matter regions, ESs in patients with epilepsy were significantly 
correlated with those in patients with BP (Spearman’s rho r=0.53, p<0.05), SCZ (r=0.53, 
p<0.05), and MDD (r=0.44, p<0.05).    
Approach for multiple comparisons correction 
Regional differences in diffusion parameters between syndromes and healthy controls 
were expressed as ESs (Cohen's d). In order to identify significant differences we adopted a 
Bonferroni correction that adjusted for testing 38 ROIs for each syndrome (p<0.001). 
However, an even more conservative approach would correct for each of the four diffusion 
metrics across the seven epilepsy syndromes. Implementing this very conservative 
Bonferroni cutoff would result in a threshold of p<0.05/(38*7*4)=4.7e-05. The combination 
of the large sample size and the observed medium to large effect sizes in the study results in 
most regional differences remaining significant even at the very conservative p-value 
threshold. However, in contrasts involving a smaller number of patients (controls compared 
to, e.g., GGE or TLE-NL) more regions would lose the "significant" label due to the reduced 
statistical power. Despite these few exceptions, the exact p-value cutoff does not alter the 
main finding that there were widespread white matter abnormalities across epilepsy 
syndromes. We report all effect sizes, confidence intervals, and p-values in supplementary 
material for researchers interested to examine these results with alternate definitions of 
statistical significance.  
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Discussion 
This multi-site DTI study in epilepsy compared data from 1,249 patients with 
common epilepsy syndromes to 1,069 healthy controls.  Data were acquired at 21 sites across 
North America, South American, Europe, and Australia and harmonized using the same post-
processing pipeline and batch effect harmonization tool.   
There were marked white matter alterations across epilepsy syndromes compared to 
controls, with the most pronounced effects in patients with TLE-HS and modest effects in 
GGE.  The anterior-midline fibers, including the CC, CGC, ACR and EC, were among the 
most affected fiber bundles across epilepsy syndromes--a finding not previously recognized 
in the literature, and one that could suggest vulnerability of these fibers to the consequences 
of epilepsy (e.g., treatments, recurrent seizures).     
Previous studies have investigated white matter alterations within a specific epilepsy 
syndrome, and our first analysis included a diverse aggregation of epilepsy syndromes to 
address the question of shared pathological changes across syndromes. This analysis revealed 
widespread reductions in FA across most association, commissural, and projection fibers 
bilaterally, with smaller effects of increased MD.  The most robust alterations were observed 
in frontocentral regions, including the genu and body of the CC, ACR, CGC, and EC.  These 
regional changes mirror results from our structural MRI findings (Whelan et al., 2018), which 
revealed subcortical atrophy and neocortical thinning in fronto-central, midline structures, 
including the thalamus, pallidum,  pre- and post central gyri, and superior frontal regions 
bilaterally.  These regions showed the strongest association with both age of seizure onset 
and disease duration.  Therefore, white matter abnormalities in these regions may be a result 
of both shared developmental (i.e., disruptions of late-myelinating pathways due to seizures) 
and degenerative (i.e., demyelination and/or axonal loss due to years of epilepsy, recurrent 
seizures, exposure to anti-epileptic drugs (AEDs), and other factors) processes.  Although 
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lower FA and higher MD have been interpreted as reflecting a combination of pathological 
processes, these differences appear to be primarily driven by higher RD, supporting the 
concept of disrupted or altered myelin rather than significant axonal loss (Arfanakis et al., 
2002; Concha et al., 2009) 
Temporal Lobe Epilepsy 
A recent imaging-based meta-analysis (Slinger et al., 2016) found that patients with 
TLE had pronounced and widespread white matter injury relative to other patient syndromes.  
We found that this pattern was much more robust and ipsilateral in patients with HS, 
particularly in hippocampal afferent and efferent tracts, including the CGH, FX/ST, and 
UNC.  The proximity of these latter white matter regions to the epileptogenic zone and being 
greater ipsilaterally than contralaterally implies that these alterations are driven by intrinsic 
factors specific to the (lateralized) TLE-HS syndrome rather than long-term effects of AEDs.  
Contrary to prior work (Ahmadi et al., 2009; Whelan et al., 2018), we did not find greater 
abnormalities in patients with left TLE relative to right TLE in either the TLE-HS or TLE-NL 
groups, nor did we find greater injury in males with TLE relative to females.  Rather, men 
with TLE-HS and TLE-NL showed higher global FA values relative to women. This 
contrasts with a previous meta-analysis which found men with focal epilepsy to be more 
vulnerable to white matter injury relative to women (Slinger et al., 2016). These findings do 
not appear to reflect differences in age, age of seizure onset, or disease duration, as these 
characteristics did not differ between men and women in our TLE cohorts. It has been 
reported that compared to age-matched women, men have greater white matter volume and 
neuronal number with fewer neuronal processes (Rabinowicz et al., 1999), which is 
hypothesized to represent fewer, thicker and more organized fibers in men compared to more 
crossing fiber tracts in women (Schmithorst et al., 2008). This hypothesis is supported by the 
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finding that higher FA in males compared to females was also observed in our healthy control 
sample.  
 Patients with TLE-NL showed a very mild pattern of white matter disruption 
compared to TLE-HS (Campos et al., 2015) (Fig. 3 and 4).  Although this may, in part, 
reflect the greater likelihood for patients with TLE-NL to have a benign form of epilepsy, 
previous studies have shown that even among drug-resistant TLE, patients with TLE-NL 
harbor less severe cortical (Bernhardt et al., 2016, 2019) and white matter (Liu et al., 2012) 
abnormalities compared to TLE-HS.  White matter disruptions in TLE-NL were notable in 
the EC and SS, both of which contain long-range association pathways.  In particular, the SS 
contains fibers of the inferior fronto-occipital fasciculus and the inferior longitudinal 
fasciculus (Cristina et al., n.d.).  These fibers course through the temporal lobe lateral to the 
CGH and FX/ST supporting data suggesting that TLE-HS and TLE-NL involve different 
epileptogenic networks (Zaveri et al., 2001; Mueller et al., 2009). However, many FA/MD 
alterations did not differ between TLE-HS and TLE-NL patients, once age of seizure onset 
and disease duration were taken into account (Fig. 5).  Thus, the magnitude of these 
differences appears to be influenced by differences in clinical characteristics.  This is 
supported by the association of an earlier age of seizure onset and longer disease duration 
with regional white matter disruption in TLE-HS, but not in TLE-NL. 
Genetic generalized epilepsy         
GGE includes several related syndromes, defined electrographically by generalized, 
bisynchronous, and symmetric activity with spike-wave or polyspike-wave discharges (Weir, 
1965; Seneviratne et al., 2012).  These syndromes have traditionally been associated with 
thalamocortical dysfunction, with some studies reporting atrophy in the thalamus (Whelan et 
al., 2018) or thalamocortical networks (Bernhardt et al., 2009), and other studies reporting no 
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structural changes relative to controls (McGill et al., 2014). Although patients with GGE 
showed modest alterations relative to patients with focal epilepsy across most fibers, these 
differences were broader than those previously observed (Slinger et al., 2016) and include 
commissural (GCC), projection (ACR) and corticocortical association pathways (EC, SLF). 
In addition, the magnitude of these changes in the ACR was similar to those observed in 
other epilepsy syndromes after adjusting for clinical and demographic characteristics (Fig. 5).  
The ACR is part of the limbic-thalamo-cortical circuitry and includes thalamic projections 
from the internal capsule to the cortex, including prominent connections to the frontal lobe 
bilaterally (Catani et al., 2002; Wakana et al., 2004). Thus, these projection fibers may be 
particularly affected in GGE, supporting their electrographic signature and previous work in 
subsets of patients with GGE, including juvenile myoclonic epilepsy suggestive of 
frontothalamic pathology (Woermann et al., 1999; Keller et al., 2011) 
Extratemporal epilepsy  
 The group of patients with non-lesional focal ExE showed the most marked 
alterations in the BCC, GCC, ACR, CGC, and EC, and showed a similar pattern to the GGE 
group of bilateral fronto-central alterations.  As frontal lobe epilepsy is the second most 
common type of focal epilepsy (Manford et al., 1992), it is likely that this group dominated 
the ExE group, explaining the predominance of fronto-midline pathology.  Unlike the TLE-
HS, neither age of seizure onset nor disease duration were associated with regional white 
matter compromise. This may be related to the heterogeneity of this patient group, their latter 
age of seizure onset and/or the fact that this non-lesional group may represent a “mild” form 
of ExE.     
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Summary 
In summary, we found shared white matter compromise across epilepsy syndromes, 
dominated by regional alterations in bilateral midline, fiber bundles.  The question arises as to 
whether these shared alterations are specific to epilepsy or are non-specific effects of a 
chronic brain disorder. Comparison of our ES to those of five other ENIGMA populations 
revealed that the pattern of microstructural compromise in epilepsy was similar to the 
patterns observed in BP, SCZ, and MDD. In particular, the CC body and genu were 
commonly affected across disorders, suggesting that microstructural compromise could 
reflect a shared patho-physiological mechanism. However, patients with epilepsy tend to 
have high rates of comorbid mood disorder (Kanner, 2007) and these were not characterized 
in our epilepsy sample. Therefore, overlap in neuropathology between our epilepsy cohort 
and major neuropsychiatric disorders could, in part, underlie the high rates of co-morbidity 
observed among these disorders. Increasing evidence suggests that neuropsychiatric disorders 
themselves are not separated by sharp neurobiological boundaries (Baker et al., 2019), but 
have overlapping of genetic influences and brain dysfunction (Brainstorm Consortium et al., 
2018; Radonjić et al., 2019). Although genetic overlap between these neuropsychiatric 
disorders and epilepsy is low, overlap in dysfunctional brain networks may be partly due to 
comorbidities, and warrants further investigation. 
 
Limitations 
First, although much effort was taken to apply post-acquisition harmonization, each 
scanner used varies in either image acquisition protocol or scanner hardware, or both, which 
increased methodological heterogeneity. Conversely,our results can be considered 
independent of any specific acquisition scheme, head coil or scanner model. Accordingly, 
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while the absence of a single, standardized MR protocol incorporates scanner variance into 
the data, it also provides breadth that enhances the generalizability of findings. The statistical 
batch normalization process ComBat corrected differences between scanner instances, but 
may not adequately accommodate the heterogeneous neuropathology of epilepsy, resulting in 
a smoothing out of differences between syndromes..  
 A second limitation is the challenge of directly ascribing lower FA and higher MD to 
demyelination and/or axonal injury. Specifically, lower FA can reflect the effects of crossing 
fibers, increases in extracellular diffusion (e.g., inflammation, edema) or other technical or 
biological factors. Therefore, advanced diffusion sequences such as high angular resolution 
diffusion imaging (HARDI) and multishell dMRI acquisitions, together with analysis of 
quantitative contrasts sensitive to tissue microstructural features and neuropathological 
investigations, would help better unravel the biological underpinnings of our findings. 
Finally, detailed clinical information was not available for all patients. Therefore, we 
could not directly assess how these diffusional changes were associated specific AED 
regimens, comorbid disorders, cognitive performances, or how they relate to clinical 
outcomes (i.e., drug resistance or post-operative seizure outcome). These data are now being 
collected across the consortium to better characterize patients and evaluate the clinical utility 
of identifying syndrome-specific and shared microstructural injury in epilepsy.   
Conclusions 
Overall, in the largest DTI mega-analysis of epilepsy, we demonstrate a pattern of 
robust white matter alterations within and across patient syndromes, revealing shared and 
unique features for each syndrome.  These microstructural alterations may reflect a number of 
pathological processes, including disrupted myelination, myelin or axonal loss due to chronic 
seizures, or increases in extracellular fluid due to inflammation. Such cross-syndrome and 
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cross-disease comparisons could help to inform gene expression studies and provide novel 
insights into shared cognitive and psychiatric co-morbidities. 
.   
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Figures and Tables 
 
Table 1. Characteristics of the patient and control samples by site. 
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Table 2. Demographic and clinical characteristics of the total sample. Post-hoc 
comparisons revealed that controls were younger than both TLE-HS groups and older than 
patients with GGE and ExE (all p-values<0.05).  Both TLE-HS groups and the left TLE-NL 
group were older than the GGE and ExE groups (p<0.05). The right TLE-HS group was older 
than both TLE-NL groups (p<0.05).  
 
  N Age (SD) Sex          
(% Male) 
Age of onset 
(SD) 
Duration of 
illness (SD) 
Controls 1,069 35.5 (11.7) 41.7 ----- ----- 
All patients 1,249 36.1 (11.2) 42.9 16.3 (11.3) 19.9 (13.0) 
L TLE-HS 319 38.3 (10.6) 43.3 14.5 (11.5) 24.2 (13.3) 
R TLE-HS 280 39.3 (10.8) 42.5 15.3 (11.6) 24.1 (13.9) 
L TLE-NL 162 36.1 (10.9) 38.3 18.8 (11.6) 17.1 (12.1) 
R TLE-NL 113 35.1 (11.4) 37.2 19.5 (12.2) 15.1 (11.2) 
GGE 182 31.8 (9.9) 44.5 14.8 (7.3) 16.8 (10.5) 
ExE 193 32.7 (11.5) 43.5 17.6 (11.1) 15.1 (11.5) 
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Figure 1. Fiber atlas.  
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Figure 2.  dMRI harmonization using ComBat. Average FA (top) and MD (bottom) 
measures across 24 scanners showing differences in mean FA measures per scanner (left) 
which are harmonized using ComBat (middle). The process corrects the variance in scanner 
without altering the biological variance expected with age (right). Red= before correction; 
Blue= after correction. 
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Figure 3. FA Effect Size Bar Graphs 
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Figure 4. MD Effect Size Bar Graphs 
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Figure 5. Syndromic difference in average FA and MD in five ROIs. Mean FA (left) and 
MD (right) for each patient syndrome, controlling for age, age2, sex, age of onset, and disease 
duration. Error bars reflect 95% confidence intervals. Significant differences are marked with 
asterisks (* for p<0.05, ** for p<0.01, *** for p<0.001). 
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Figure 6. A).  Heat map of FA effect sizes for the “all epilepsies” group compared to 
those in four other ENIGMA disorders:  SCZ = schizophrenia; BP = bipolar disorder; 
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MDD = major depressive disorder.  B). Radar plot of the four disorders that showed 
significant correlations across white matter tracts.  Positive values reflect patient group 
values were on average higher than controls, whereas negative values reflect cases where 
patient group values were on average lower than that of controls.   
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